Epidemiological Insights, Genotypic Variations, and Treatment Efficacy in Chronic Hepatitis C Patients Treated with Direct-Acting Antivirals: Findings from a Cohort Study in Istanbul, Türkiye - Scorecard - MDSpire
Advertisement
Epidemiological Insights, Genotypic Variations, and Treatment Efficacy in Chronic Hepatitis C Patients Treated with Direct-Acting Antivirals: Findings from a Cohort Study in Istanbul, Türkiye
Clinical Scorecard: Epidemiological Insights, Genotypic Variations, and Treatment Efficacy in Chronic Hepatitis C Patients Treated with Direct-Acting Antivirals: Findings from a Cohort Study in Istanbul, Türkiye
At a Glance
Category
Detail
Condition
Chronic Hepatitis C (CHC)
Key Mechanisms
HCV infection leading to liver-related morbidity and mortality, with potential progression to cirrhosis and hepatocellular carcinoma.
Target Population
Patients aged ≥ 18 years diagnosed with CHC, including high-risk groups such as IVDUs and incarcerated individuals.
Care Setting
Infectious diseases outpatient clinic in Türkiye.
Key Highlights
Approximately 50 million people globally are living with CHC.
Direct-acting antivirals (DAAs) have significantly improved access to curative therapy since 2016.
Genotype 1 predominates, but evolving patterns are observed among younger and high-risk populations.
Real-world data is essential for evaluating treatment outcomes in underrepresented populations.
Sustained virological response at 12 weeks (SVR12) is a key measure of treatment efficacy.
Guideline-Based Recommendations
Diagnosis
Diagnosis of CHC should include HCV-RNA testing and assessment of liver status.
Management
DAAs should be administered based on genotype and patient characteristics.
Monitoring & Follow-up
Monitor for SVR12 and assess for adverse events post-treatment.
Risks
Consider risks associated with HCV transmission through unsafe medical practices and IVDU.
Patient & Prescribing Data
233 patients with CHC who completed treatment and had available SVR12 data.
DAAs such as sofosbuvir and glecaprevir/pibrentasvir have shown efficacy in achieving SVR12.
Clinical Best Practices
Incorporate real-world data to inform treatment strategies.
Evaluate HCV genotype distribution to tailor therapy.
Ensure follow-up for SVR12 assessment to monitor treatment success.
The nurse practitioner profession claims the No. 1 spot across three categories in the U.S. News & World Report 2026 Best Jobs rankings for the third consecutive year.
